Drug updated on 5/17/2024
Dosage Form | Tablet (oral: 60 mg, 100 mg, 150 mg) |
Drug Class | Tetracycline class antibacterials |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ≥ 9 years of age.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Sarecycline (Seysara) is approved for the management of inflammatory lesions of non-nodular moderate to severe acne vulgaris in individuals aged 9 years and older.
- One systematic review/meta-analysis compared the safety and effectiveness of sarecycline with other antibiotics in the tetracycline class, such as doxycycline, minocycline, and tetracycline.
- The study involved a large sample of 226,019 pediatric and adult patients suffering from acne. This sizeable sample size suggests the results can be applied across typical demographic groups encountered in various settings.
- Sarecycline showed effectiveness in treating both facial and truncal acne, indicating a potentially broader scope of action compared with doxycycline, minocycline, or tetracycline.
- Concerns regarding antibiotic resistance and gut dysbiosis were highlighted. Although the study did not provide a detailed comparison of these issues among the different antibiotics, sarecycline's status as a novel narrow-spectrum tetracycline suggests it might have a reduced impact on gut flora and may contribute less to antibiotic resistance.
- The inclusion of both pediatric and adult populations without specifying subgroup considerations underscores the drug's wide applicability for various age groups suffering from Acne Vulgaris.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Seysara (sarecycline) Prescribing Information. | 2021 | Almirall LLC, Malvern, PA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Oral tetracyclines and acne: a systematic review for dermatologists. | 2020 | Journal of Drugs in Dermatology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Guidelines of care for the management of acne vulgaris. | 2024 | Journal of the American Academy of Dermatology |